NextCure Inc NXTC
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if NXTC is a good fit for your portfolio.
News
-
NextCure and LCB Present Preclinical Data on B7-H4 Antibody Drug Conjugate at AACR 2024
-
NextCure Appoints Dr. Rakesh Dixit to Scientific Advisory Board
-
NextCure to Present at 23rd Annual Needham Virtual Healthcare Conference
-
NextCure Provides Business Update and Reports Full Year 2023 Financial Results
-
Thinking about buying stock in Marathon Digital, Assertio, Ocean Biomedical, Terns Pharmaceuticals, or NextCure?
-
NextCure Publishes Preclinical Data Demonstrating Function of FLRT3 as a T Cell Inhibitor in Science Advances
Trading Information
- Previous Close Price
- $1.64
- Day Range
- $1.47–1.66
- 52-Week Range
- $0.98–2.57
- Bid/Ask
- $1.44 / $1.69
- Market Cap
- $42.13 Mil
- Volume/Avg
- 116,132 / 304,862
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases, and NC181, for Alzheimer’s disease.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 82
- Website
- https://www.nextcure.com
Comparables
Valuation
|
Metric
|
NXTC
|
KURA
|
MRSN
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 0.40 | 3.48 | 12.30 |
Price/Sales | — | — | 11.85 |
Price/Cash Flow | — | — | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
NXTC
|
KURA
|
MRSN
|
|---|---|---|---|
Quick Ratio | 15.73 | 12.02 | 3.29 |
Current Ratio | 16.38 | 12.26 | 3.36 |
Interest Coverage | — | −107.04 | −44.11 |
Quick Ratio
NXTC
KURA
MRSN
Profitability
|
Metric
|
NXTC
|
KURA
|
MRSN
|
|---|---|---|---|
Return on Assets (Normalized) | −35.26% | −27.08% | −49.57% |
Return on Equity (Normalized) | −38.90% | −29.62% | −211.52% |
Return on Invested Capital (Normalized) | −37.17% | −31.62% | −146.81% |
Return on Assets
NXTC
KURA
MRSN
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Ntzgvzhy | Qfwd | $553.3 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Kfqrbwyf | Jcktkh | $101.6 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Vshrtpxr | Vdnpnd | $98.9 Bil | |
MRNA
| Moderna Inc | Xwqsvkgp | Zzxmw | $39.7 Bil | |
ARGX
| argenx SE ADR | Xnxlqdxs | Lnmv | $21.5 Bil | |
BNTX
| BioNTech SE ADR | Gpptztcp | Hnd | $20.8 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Smlwgprky | Zrqpxcn | $18.4 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Vtkwdbgw | Rjnxd | $17.2 Bil | |
RPRX
| Royalty Pharma PLC Class A | Zvggvxpbp | Tyxhgc | $12.3 Bil | |
INCY
| Incyte Corp | Pxhvtlwx | Ywyscq | $11.8 Bil |